Abstract
Psychotic symptoms are considered a clinical predictor of poor outcome in bipolar disorder (BD). The misdiagnosis of psychotic BD (BD-P) with schizophrenia, schizoaffective disorder, or delusional disorder is very common. The identification of biological markers for BD-P would contribute to establish an early diagnosis and to define a proper treatment, to improve outcome of BD-P patients.
A case of a patient suffering from BD-P has been described, focusing on neuroimaging, neuropsychological, and inflammation data that could be considered potential biomarkers of BD-P.
The patient was a 36-year-old female. During her two hospitalizations, inflammatory and metabolic markers were all normal, except for lower plasma levels of vitamin A. After giving her written informed consent, epigenetic tests were performed, showing a significantly different expression of some miRNAs than healthy controls (HC). The magnetic resonance imaging (MRI) showed hypoplasia of the cerebellar vermis and a small left peritrigonal area of hyperintensity in T2 sequence. The only neuropsychological deficit appeared in the motor task. The positron emission tomography (PET) showed a bilateral hypermetabolism in the frontal cortex, cingulate, and striatum.
This case demonstrated that biological markers may be useful to predict outcome of psychotic bipolar patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Fagiolini A, Forgione R, Maccari M, et al. Prevalence, chronicity, burden and borders of bipolar disorder. J Affect Disord. 2013;148:161–9.
Dickerson F, Stallings C, Origoni A, et al. A combined marker of inflammation in individuals with mania. PLoS One. 2013;e73520:8.
Goldstein BI, Young LT. Toward clinically applicable biomarkers in bipolar disorder: focus on BDNF, inflammatory markers, and endothelial function. Curr Psychiatry Rep. 2013;15:425.
Frey BN, Andreazza AC, Houenou J, et al. Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Aust N Z J Psychiatry. 2013;47:321–32.
Schroeter ML, Sacher J, Steiner J, et al. Serum S100B represents a new biomarker for mood disorders. Curr Drug Targets. 2013;14:1237–48.
Brugue E, Colom F, Sanchez-Moreno J, et al. Depression subtypes in bipolar I and II disorders. Psychopathology. 2008;41:111–4.
Mantere O, Suominen K, Leppämäki S, et al. The clinical characteristics of DSM-IV bipolar I and II disorders: baseline findings from the Jorvi bipolar study (JoBS). Bipolar Disord. 2004;6:395–405.
Keck PE Jr, McElroy SL, Havens JR, et al. Psychosis in bipolar disorder: phenomenology and impact on morbidity and course of illness. Compr. Psychiatry. 2003;44:263–9.
Zenisek R, Thaler N, Ringdahl E, et al. C-29Intellectual ability and functional outcome in bipolar disorder and schizophrenia. Arch Clin Neuropsychol. 2014;29:582–3.
Østergaard SD, Bertelsen A, Nielsen J, et al. The association between psychotic mania, psychotic depression and mixed affective episodes among 14.529 patients with bipolar disorder. J Affect Disord. 2013;147:44–50.
Vythilingam M, Chen J, Bremner JD, et al. Psychotic depression and mortality. Am J Psychiatry. 2003;160:574–6.
Coryell W, Leon AC, Turvey C, et al. The significance of psychotic features in manic episodes: a report from the NIMH collaborative study. J Affect Disord. 2001;67:79–88.
Kessing LV. Subtypes of manic episodes according to ICD-10: prediction of time to remission and risk of relapse. J Affect Disord. 2004;81:279–85.
Tohen M, Zarate CA Jr, Hennen J, et al. The McLean-Harvard first-episode mania study: prediction of recovery and first recurrence. Am J Psychiatry. 2003;160:2099–107.
Azorin JM, Akiskal H, Hantouche E. The mood-instability hypothesis in the origin of mood-congruent versus mood-incongruent psychotic distinction in mania: validation in a French National Study of 1090 patients. J Affect Disord. 2006;96:215–23.
Kessing LV. Subtypes of depressive episodes according to ICD-10: prediction of risk of relapse and suicide. Psychopathology. 2003;36:285–91.
Buoli M, Caldiroli A, Altamura AC. Psychotic versus non-psychotic major depressive disorder: a comparative naturalistic study. Asian J Psychiatr. 2013;6:333–7.
Altamura AC, Dell’Osso B, Berlin HA, et al. Duration of untreated illness and suicide in bipolar disorder: a naturalistic study. Eur Arch Psychiatry Clin Neurosci. 2010;260:385–91.
Birnbaum HG, Shi L, Dial E, et al. Economic consequences of not recognizing bipolar disorder patients: across-sectional descriptive analysis. J Clin Psychiatry. 2003;64:1201–9.
Altamura AC, Buoli M, Caldiroli A, et al. Misdiagnosis, duration of untreated illness (DUI) and outcome in bipolar patients with psychotic symptoms: a naturalistic study. J Affect Disord. 2015;182:70–5.
Lin A, Reniers RL, Wood SJ. Clinical staging in severe mental disorder: evidence from neurocognition and neuroimaging. Br J Psychiatry Suppl. 2013;54:s11–7.
Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10:799–812.
Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–35.
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56.
Buoli M, Caldiroli A, Cumerlato Melter C, et al. Biological aspects and candidate biomarkers for psychotic bipolar disorder: a systematic review. Psychiatry Clin Neurosci. 2016;70:227–44.
Goes FS, Willour VL, Zandi PP, et al. Bipolar disorder Phenome group; NIMH genetics initiative bipolar disorder consortium. Family-based association study of Neuregulin 1 with psychotic bipolar disorder. Am J Med Genet B Neuropsychiatr Genet. 2009;150B:693–702.
Prata DP, Breen G, Osborne S, et al. An association study of the neuregulin 1 gene, bipolar affective disorder and psychosis. Psychiatr Genet. 2009;19:113–6.
Cheng R, Juo SH, Loth JE, et al. Genome-wide linkage scan in a large bipolar disorder sample from the National Institute of Mental Health genetics initiative suggests putative loci for bipolar disorder, psychosis, suicide, and panic disorder. Mol Psychiatry. 2006;11:252–60.
Goes FS, Zandi PP, Miao K, et al. Mood-incongruent psychotic features in bipolar disorder: familial aggregation and suggestive linkage to 2p11-q14 and 13q21-33. Am J Psychiatry. 2007;164:236–47.
Kremeyer B, García J, Müller H, et al. Genome-wide linkage scan of bipolar disorder in a Colombian population isolate replicates loci on chromosomes 7p21-22, 1p31, 16p12 and 21q21-22 and identifies a novel locus on chromosome 12q. Hum Hered. 2010;70:255–68.
Olsson SK, Sellgren C, Engberg G, et al. Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder. Bipolar Disord. 2012;14:719–26.
Johansson AG, Nikamo P, Schalling M, Landén M. Polymorphisms in AKR1C4 and HSD3B2 and differences in serum DHEAS and progesterone are associated with paranoid ideation during mania or hypomania in bipolar disorder. Eur Neuropsychopharmacol. 2012;22:632–40.
Severance EG, Dupont D, Dickerson FB, et al. Immune activation by casein dietary antigens in bipolar disorder. Bipolar Disord. 2010;12:834–42.
Severance EG, Gressitt KL, Yang S, et al. Seroreactive marker for inflammatory bowel disease and associations with antibodies to dietary proteins in bipolar disorder. Bipolar Disord. 2014;16:230–40.
Narayanan B, O’Neil K, Berwise C, et al. Resting state electroencephalogram oscillatory abnormalities in schizophrenia and psychotic bipolar patients and their relatives from the bipolar and schizophrenia network on intermediate phenotypes study. Biol Psychiatry. 2014;76:456–65.
Cabranes JA, Ancín I, Santos JL, et al. P50 sensory gating is a trait marker of the bipolar spectrum. Eur Neuropsychopharmacol. 2013;23:721–7.
Olincy A, Martin L. Diminished suppression of the P50 auditory evoked potential in bipolar disorder subjects with a history of psychosis. Am J Psychiatry. 2005;162:43–9.
Sánchez-Morla EM, García-Jiménez MA, Barabash A, et al. P50 sensory gating deficit is a common marker of vulnerability to bipolar disorder and schizophrenia. Acta Psychiatr Scand. 2008;117:313–8.
Schulze KK, Hall MH, McDonald C, et al. P50 auditory evoked potential suppression in bipolar disorder patients with psychotic features and their unaffected relatives. Biol Psychiatry. 2007;62:121–8.
Carroll CA, Kieffaber PD, Vohs JL, et al. Contributions of spectral frequency analyses to the study of P50 ERP amplitude and suppression in bipolar disorder with or without a history of psychosis. Bipolar Disord. 2008;10:776–87.
Patterson JV, Sandman CA, Ring A, et al. An initial report of a new biological marker for bipolar disorder: P85 evoked brain potential. Bipolar Disord. 2009;11:596–609.
Reite M, Teale P, Rojas DC, et al. Bipolar disorder: anomalous brain asymmetry associated with psychosis. Am J Psychiatry. 1999;156:1159–63.
Patterson JV, Sandman CA, Jin Y, et al. Gating of a novel brain potential is associated with perceptual anomalies in bipolar disorder. Bipolar Disord. 2013;15:314–25.
Hamm JP, Ethridge LE, Shapiro JR, et al. Spatiotemporal and frequency domain analysis of auditory paired stimuli processing in schizophrenia and bipolar disorder with psychosis. Psychophysiology. 2012;49:522–30.
Mahon PB, Lee DS, Trinh H, et al. Morphometry of the amygdala in schizophrenia and psychotic bipolar disorder. Schizophr Res. 2015;164:199–202.
Nenadic I, Maitra R, Langbein K, et al. Brain structure in schizophrenia vs. psychotic bipolar I disorder: a VBM study. Schizophr Res. 2015;165:212–9.
Ratnanather JT, Poynton CB, Pisano DV, et al. Morphometry of superior temporal gyrus and planum temporale in schizophrenia and psychotic bipolar disorder. Schizophr Res. 2013;150:476–83.
Ivleva EI, Bidesi AS, Keshavan MS, et al. Gray matter volume as an intermediate phenotype for psychosis: bipolar-schizophrenia network on intermediate phenotypes (B-SNIP). Am J Psychiatry. 2013;170:1285–96.
McDonald C, Bullmore E, Sham P, et al. Regional volume deviations of brain structure in schizophrenia and psychotic bipolar disorder: computational morphometry study. Br J Psychiatry. 2005;186:369–77.
Yüksel C, McCarthy J, Shinn A, et al. Gray matter volume in schizophrenia and bipolar disorder with psychotic features. Schizophr Res. 2012;138:177–82.
Radaelli D, Poletti S, Gorni I, et al. Neural correlates of delusion in bipolar depression. Psychiatry Res. 2014;221:1–5.
Tost H, Ruf M, Schmäl C, et al. Prefrontal-temporal gray matter deficits in bipolar disorder patients with persecutory delusions. J Affect Disord. 2010;120:54–61.
Edmiston EE, Wang F, Kalmar JH, et al. Lateral ventricle volume and psychotic features in adolescents and adults with bipolar disorder. Psychiatry Res. 2011;194:400–2.
Strasser HC, Lilyestrom J, Ashby ER, et al. Hippocampal and ventricular volumes in psychotic and nonpsychotic bipolar patients compared with schizophrenia patients and community control subjects: a pilot study. Biol Psychiatry. 2005;57:633–9.
Daros AR, Ruocco AC, Reilly JL, et al. Facial emotion recognition in first-episode schizophrenia and bipolar disorder with psychosis. Schizophr Res. 2014;153:32–7.
Ruocco AC, Reilly JL, Rubin LH, et al. Emotion recognition deficits in schizophrenia-spectrum disorders and psychotic bipolar disorder: findings from the bipolar-schizophrenia network on intermediate phenotypes (B-SNIP) study. Schizophr Res. 2014;158:105–12.
Thaler NS, Allen DN, Sutton GP, et al. Differential impairment of social cognition factors in bipolar disorder with and without psychotic features and schizophrenia. J Psychiatr Res. 2013;47:2004–10.
Aminoff SR, Hellvin T, Laerber TV, et al. Neurocognitive features in subgroups of bipolar disorder. Bipolar Disord. 2013;15:272–83.
Frydecka D, Eissa AM, Hewedi DH, et al. Impairments of working memory in schizophrenia and bipolar disorder: the effect of history of psychotic symptoms and different aspects of cognitive task demands. Front Behav Neurosci. 2014;8:416.
Simonsen C, Sundet K, Vaskinn A, et al. Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis rather than diagnostic group. Schizophr Bull. 2011;37:73–83.
Zanelli J, Reichenberg A, Morgan K, et al. Specific and generalized neuropsychological deficits: a comparison of patients with various first-episode psychosis presentations. Am J Psychiatry. 2010;167:78–85.
Ancín I, Cabranes JA, Santos JL, et al. Executive deficits: a continuum schizophrenia-bipolar disorder or specific to schizophrenia? J Psychiatr Res. 2013;47:1564–71.
Savitz J, van der Merwe L, Stein DJ, et al. Neuropsychological status of bipolar I disorder: impact of psychosis. Br J Psychiatry. 2009;194:243–51.
Selva G, Salazar J, Balanzá-Martínez V, et al. Bipolar I patients with and without a history of psychotic symptoms: do they differ in their cognitive functioning? J Psychiatr Res. 2007;41:265–72.
Banala RR, Karnati PR. Vitamin a deficiency: an oxidative stress marker in sodium fluoride (NaF) induced oxidative damage in developing rat brain. Int J Dev Neurosci. 2015;47:298–303.
Gautam M, Agrawal M, Gautam M, et al. Role of antioxidants in generalized anxiety disorder and depression. Indian J Psychiatry. 2012;54:244–7.
Chowdhury MI, Hasan M, Islam MS, et al. Elevated serum MDA and depleted non-enzymatic antioxidants, macro-minerals and trace elements are associated with bipolar disorder. J Trace Elem Med Biol. 2017;39:162–8.
Tamminga CA, Ivleva EI, Keshavan MS, et al. Clinical phenotypes of psychosis in the bipolar-schizophrenia network on intermediate phenotypes (B-SNIP). Am J Psychiatry. 2013;170:1263–74.
Altamura AC, Serati M, Albano A, et al. An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses. Eur Arch Psychiatry Clin Neurosci. 2011;261:489–508.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Self-Assessment
Self-Assessment
-
1.
What is the prevalence of bipolar disorder?
-
(a) 5%
-
(b) 20%
-
(c) 80%
-
(d) 1–2%
-
(e) 10%
-
-
2.
Which abnormality has been found in manic BD patients?
-
(a) Increased BDNF levels
-
(b) Increased inflammatory markers
-
(c) Decreased inflammatory markers
-
(d) Increased serum antioxidants levels
-
(e) Decreased BDNF levels
-
-
3.
Psychotic bipolar patients present:
-
(a) Worse prognosis than unipolar and BD-NP patients
-
(b) Better prognosis than unipolar and BD-NP patients
-
(c) Worse prognosis than SKZ patients
-
(d) Better prognosis than schizoaffective patients
-
(e) We do not have data about BD-P patients’ prognosis
-
-
4.
Identification of biological markers for BD-P:
-
(a) Would hinder the diagnostic and therapeutic process
-
(b) Could help patients to decide independently which treatment is the best
-
(c) Would help clinicians to promptly diagnose the disorder and to properly identify the treatment
-
(d) Could help clinicians to decide independently which treatment is the best
-
(e) Would hinder the clinical staging processing, worsening outcome in the long term
-
-
5.
Vitamin A (retinol) is:
-
(a) The forerunner of beta-carotene
-
(b) An enzymatic antioxidant
-
(c) Fundamental for metabolism of lipids and proteins
-
(d) A cholesterol derivative
-
(e) A nonenzymatic antioxidant
-
Rights and permissions
Copyright information
© 2019 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Buoli, M., Caldiroli, A. (2019). Psychotic Bipolar Disorder. In: Altamura, A., Brambilla, P. (eds) Clinical Cases in Psychiatry: Integrating Translational Neuroscience Approaches. Springer, Cham. https://doi.org/10.1007/978-3-319-91557-9_4
Download citation
DOI: https://doi.org/10.1007/978-3-319-91557-9_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-91556-2
Online ISBN: 978-3-319-91557-9
eBook Packages: MedicineMedicine (R0)